Rituximab therapy in pemphigus and other autoantibody-mediated diseases
Sign Up to like & getrecommendations! Published in 2017 at "F1000Research"
DOI: 10.12688/f1000research.9476.1
Abstract: Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has… read more here.
Keywords: mediated diseases; pemphigus autoantibody; autoantibody mediated; rituximab therapy ... See more keywords